背景:粪便钙卫蛋白是评估儿科胃肠道疾病肠道炎症的有价值的生物标志物。然而,其作用,优点,必须全面阐明各种条件下的弊端。
目的:探讨粪便钙卫蛋白在小儿胃肠道疾病中的作用,包括它的优点和局限性。
方法:在PubMed上进行了全面搜索,PubMedCentral,谷歌学者,和其他科学研究引擎,直到2024年2月24日。这篇综述包括88篇研究文章,56篇评论文章,六项荟萃分析,两次系统审查,两份共识文件,给编辑的两封信.
结果:粪便钙卫蛋白是一种非侵入性标志物,用于检测肠道炎症和监测儿科疾病活动,如功能性胃肠病,炎症性肠病,乳糜泻,冠状病毒病2019-诱发的胃肠道疾病,胃肠炎,和囊性纤维化相关的肠道病理学。然而,它缺乏特异性和对各种混杂因素的敏感性给解释带来了挑战。尽管有这些限制,粪便钙卫蛋白在诊断方面具有显著优势,监测,和管理儿科胃肠道疾病。
结论:粪便钙卫蛋白有望成为儿科胃肠病学的有价值的工具,提供对疾病活动的见解,治疗反应,和预后。需要标准化的协议和指南来优化其临床实用性并减轻解释挑战。需要进一步的研究来解决已确定的局限性,并增强我们对小儿胃肠道疾病中粪便钙卫蛋白的理解。
BACKGROUND: Fecal calprotectin is a valuable biomarker for assessing intestinal inflammation in pediatric gastrointestinal diseases. However, its role, pros, and cons in various conditions must be comprehensively elucidated.
OBJECTIVE: To explore the role of fecal calprotectin in pediatric gastrointestinal diseases, including its advantages and limitations.
METHODS: A comprehensive search was conducted on PubMed, PubMed Central, Google Scholar, and other scientific research engines until February 24, 2024. The review included 88 research articles, 56 review articles, six meta-analyses, two systematic reviews, two consensus papers, and two letters to the editors.
RESULTS: Fecal calprotectin is a non-invasive marker for detecting intestinal inflammation and monitoring disease activity in pediatric conditions such as functional gastrointestinal disorders, inflammatory bowel disease, coeliac disease, coronavirus disease 2019-induced gastrointestinal disorders, gastroenteritis, and cystic fibrosis-associated intestinal pathology. However, its lack of specificity and susceptibility to various confounding factors pose challenges in interpretation. Despite these limitations, fecal calprotectin offers significant advantages in diagnosing, monitoring, and managing pediatric gastrointestinal diseases.
CONCLUSIONS: Fecal calprotectin holds promise as a valuable tool in pediatric gastroenterology, offering insights into disease activity, treatment response, and prognosis. Standardized protocols and guidelines are needed to optimize its clinical utility and mitigate interpretation challenges. Further research is warranted to address the identified limitations and enhance our understanding of fecal calprotectin in pediatric gastrointestinal diseases.